Integra Lifesciences (NASDAQ:IART) Downgraded by ValuEngine

ValuEngine downgraded shares of Integra Lifesciences (NASDAQ:IART) from a hold rating to a sell rating in a research report report published on Thursday, ValuEngine reports.

A number of other analysts have also recently weighed in on IART. BidaskClub raised shares of Integra Lifesciences from a hold rating to a buy rating in a report on Saturday, July 27th. Zacks Investment Research cut shares of Integra Lifesciences from a buy rating to a hold rating and set a $56.00 price objective on the stock. in a report on Thursday, June 20th. JMP Securities increased their price objective on shares of Integra Lifesciences to $75.00 in a report on Thursday, July 25th. Oppenheimer raised their target price on shares of Integra Lifesciences from $65.00 to $70.00 and gave the company an outperform rating in a research note on Thursday, July 25th. Finally, Royal Bank of Canada set a $66.00 target price on shares of Integra Lifesciences and gave the company a hold rating in a research note on Friday, July 26th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the company. The stock currently has a consensus rating of Hold and a consensus target price of $61.92.

Shares of NASDAQ:IART traded down $1.12 on Thursday, reaching $61.26. 9,301 shares of the company’s stock were exchanged, compared to its average volume of 394,491. The company has a market cap of $5.34 billion, a price-to-earnings ratio of 25.39, a price-to-earnings-growth ratio of 1.96 and a beta of 1.08. Integra Lifesciences has a fifty-two week low of $42.14 and a fifty-two week high of $66.41. The business has a 50-day simple moving average of $55.79. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.76 and a quick ratio of 1.82.

Integra Lifesciences (NASDAQ:IART) last issued its earnings results on Wednesday, July 24th. The life sciences company reported $0.73 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.08. Integra Lifesciences had a net margin of 6.76% and a return on equity of 16.30%. The company had revenue of $383.60 million for the quarter, compared to analysts’ expectations of $373.29 million. During the same period in the prior year, the company earned $0.60 earnings per share. The firm’s revenue was up 4.8% compared to the same quarter last year. Sell-side analysts anticipate that Integra Lifesciences will post 2.73 EPS for the current year.

In other news, VP Daniel L. Reuvers sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, July 24th. The shares were sold at an average price of $60.00, for a total transaction of $300,000.00. Following the completion of the transaction, the vice president now owns 35,392 shares in the company, valued at approximately $2,123,520. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Lisa Evoli sold 2,380 shares of the firm’s stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $63.00, for a total transaction of $149,940.00. Following the transaction, the insider now owns 2,588 shares of the company’s stock, valued at approximately $163,044. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 36,844 shares of company stock valued at $2,085,117. Insiders own 4.50% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in the business. Champlain Investment Partners LLC boosted its holdings in shares of Integra Lifesciences by 1.4% in the first quarter. Champlain Investment Partners LLC now owns 5,473,820 shares of the life sciences company’s stock worth $305,001,000 after buying an additional 77,845 shares during the period. Janus Henderson Group PLC boosted its holdings in shares of Integra Lifesciences by 13.1% in the second quarter. Janus Henderson Group PLC now owns 3,248,870 shares of the life sciences company’s stock worth $181,449,000 after buying an additional 375,546 shares during the period. Clearbridge Investments LLC boosted its holdings in shares of Integra Lifesciences by 21.2% in the first quarter. Clearbridge Investments LLC now owns 2,442,164 shares of the life sciences company’s stock worth $136,077,000 after buying an additional 426,578 shares during the period. Vaughan Nelson Investment Management L.P. boosted its holdings in shares of Integra Lifesciences by 26.1% in the first quarter. Vaughan Nelson Investment Management L.P. now owns 1,110,177 shares of the life sciences company’s stock worth $61,860,000 after buying an additional 230,010 shares during the period. Finally, Fisher Asset Management LLC boosted its holdings in shares of Integra Lifesciences by 0.7% in the second quarter. Fisher Asset Management LLC now owns 781,166 shares of the life sciences company’s stock worth $43,628,000 after buying an additional 5,698 shares during the period. Institutional investors own 82.17% of the company’s stock.

About Integra Lifesciences

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Featured Article: Moving Average – How it Helps Investors in Stock Selection

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.